Apremilast, an Oral Phophodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Results From the PALACE 4 Phase 3, Randomized, Controlled Trial

Abstract

Abstract is not available.